Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Retatrutide for Sale > Factory Direct Retatrutide Raw Material for Research Purpose
Factory Direct Retatrutide Raw Material for Research Purpose buy - large image1
Factory Direct Retatrutide Raw Material for Research Purpose buy - image1
Factory Direct Retatrutide Raw Material for Research Purpose buy - image2
Factory Direct Retatrutide Raw Material for Research Purpose buy - image3
Factory Direct Retatrutide Raw Material for Research Purpose buy - image4
Factory Direct Retatrutide Raw Material for Research Purpose buy - image5
Factory Direct Retatrutide Raw Material for Research Purpose buy - image6

Factory Direct Retatrutide Raw Material for Research Purpose

TDS 7625 Inquiries

Unit Price:

$35/MT FOB

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Industrial Grade

Content:

99%

Port:

上海

Brand:

Huaian Camelot

Packaging:

5mg/10mg/15mg/20mg

Sample Available:

Yes

Price valid (until):

2026-12-12

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents
Average Lead Time:
5 days
Qualification:
Main Products:

Peptide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 1
    Flora
    ws+85264686484
    If you want to know full specifications, purity, price, MOQ and batch COA of Retatrutide and other research peptides, feel free to contact me privately. I will send you the complete product details and quotation
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 2
    Retatrutide
    Retatrutide is a first-in-class, next-generation triple metabolic receptor agonist peptide, currently a subject of intense research interest in the fields of metabolism and body composition. Unlike traditional dual-target agonists, a single molecule of retatrutide can simultaneously activate three key metabolic receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor (GCGR). The synergistic effect across these three pathways represents its primary differentiating advantage over other GLP-based peptides.
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 3
    Retatrutide
    A substantial body of published data from Phase II and Phase III clinical trials underscores the research potential of retatrutide. Administered on a once-weekly dosing regimen, retatrutide demonstrates clear, dose-dependent changes in body composition. In long-term follow-ups of high-dose groups, the average reduction in body weight reached 24%–28%; the vast majority of participants achieved a weight loss of over 5%, with more than 80% experiencing a reduction of 15% or greater. Beyond changes in body weight, the studies also observed reductions in waist circumference and visceral fat, improvements in hepatic fat deposition, and concurrent favorable shifts in various cardiometabolic markers. Among participants with co-existing glucose metabolism disorders, glycated hemoglobin (HbA1c) levels also showed a significant decline, highlighting the drug's broad research value in the metabolic domain.
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 4
    About Logistics
    We offer a variety of flexible logistics and payment solutions to meet the specific requirements of your orders.
    Our shipping options include DHL, FedEx, UPS, TNT, EMS, as well as air and sea freight. We will select the most suitable and reliable shipping method for you, ensure secure packaging, and provide a tracking number once your order has been dispatched.
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 5
    Payment Methods
    We support a diverse range of cross-border payment channels—including corporate bank transfers, Wise, and Alibaba Trade Assurance—to accommodate the varying payment preferences of your overseas clients. These methods ensure a transparent, traceable fund flow, providing a secure, stable, and efficient way to settle cross-border payments.
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 6
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 7
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 8
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 9
    About Inventory
    We maintain sufficient stock for our research peptides. Stable inventory enables fast arrangement and quick shipment once your order is confirmed. Bulk orders are also supported. Feel free to message me for the latest stock status and quotation.
      Product Name  Retatrutide
     Category  Triple Receptor Agonist Peptide (Research-grade Raw Peptide)
     Target  GLP-1 Receptor + GIP Receptor + Glucagon (GCGR) Receptor
     Mechanism  Triple-target synergy: appetite regulation, satiety enhancement, higher resting fat oxidation, improved glucose metabolism
      Appearance  White to off-white lyophilized powder
     Purity (HPLC)  99%
     COA  HPLC + MS, COA provided with each batch
     Storage  Store in cool, dark, sealed conditions
     Shipping  DHL / FedEx / UPS / TNT / EMS / Air & Sea Freight
     Payment  PayPal / T/T /  Visa / MasterCard
     Stock  Adequate stock, quick dispatch after order confirmation
      Research Use  Laboratory & scientific research on body composition and metabolism
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 10
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 11
    Customer Feedback
    We have gained consistent positive feedback from researchers and distributors worldwide.
    Our clients recognize our reliable peptide quality, stable batch consistency, responsive communication and on-time shipment.
    If you would like to know more real reviews or case references, please contact me privately.
    24-hour response to all inquiries
    We supply peptides, APIs and intermediates to meet your demands. We guarantee a 24-hour reply to your inquiries. Our raw materials go through strict screening, and the QC team conducts comprehensive quality inspection on every product before shipment. We provide competitive prices and fast delivery. After shipment, we will track logistics information for you every two days until you receive the goods. If you have any questions upon receipt, please contact us and we will provide corresponding solutions. 100% safe delivery is guaranteed.
    Shop Retatrutide  Next-Gen Triple Receptor Agonist Peptide Raw Material-Detailed Image 12
    Why Choose Us
    ✅ Supply peptides, APIs & intermediates customized for your needs
    ✅ 24-hour response to all inquiries
    ✅ Rigorous raw material selection. QC full inspection before shipment
    ✅ Competitive prices & fast lead time
    ✅ Bi-daily logistics tracking after dispatch. Post-delivery support & solutions available
    ✅ 100% safe delivery guarantee
    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Certificates

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Polypeptide

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760 ; NCT05882045 ; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptide

    Location:

    Room 107, Building A1, No. 66 Hechang Road

    Payment Terms:

    TT against copy of documents

    Average lead Time:

    5 days

    Year of Establishment:

    2025

    Huaian Camelot Cosmetics Co., Ltd. was founded in 2000, with its registered address at Room 107, Building A1, No. 66 Hechang Road, Huai'an Economic and Technological Development Zone, Jiangsu Province. Leveraging the geographical advantages and industrial resources of the zone, the company strives to build a comprehensive commercial enterprise integrating cosmetics sales, and diversified daily necessities supply.
    Main Business
    Focusing on cosmetics as its core business, the company also operates a wide range of daily-use cosmetic products. Its primary business scope is as follows:
    Cosmetics
    Wholesale and retail of cosmetics, personal hygiene products and daily chemical products.
    Health Products & E-commerce
    Corporate Advantages
    The company features flexible product portfolio capabilities. It caters to retail demands for cosmetics and daily chemicals from end consumers, Meanwhile, we actively expand online and overseas sales channels to extend our service coverage via the "Internet Plus" model.
    Development Vision
    Going forward, Huaian Camelot Cosmetics Co., Ltd. will adhere to the business philosophy of Quality Oriented, Diversified Integration and Innovation-driven. We will further expand our presence in the cosmetics and daily chemical industries, and grow into an influential comprehensive supply chain service provider in the region.

  • Inquiry History
    7625 Inquiries
    Country Product Purchase Quantity Date Posted
    United Arab Emirates

    Retatrutide

    1 PCS Nov 16, 2026
    Belgium

    retatrutide

    10 20' Fcl Nov 16, 2026
    United States

    Retatrutide

    3 MT Nov 15, 2026
    Sweden

    Retatrutide RT30

    300 MG Nov 14, 2026
    Puerto Rico

    Retatrutide

    100 PCS Nov 14, 2026
    France

    Rétatrutide

    10 PCS Nov 14, 2026
    United States

    Retatrutide

    1 MT Nov 14, 2026
    Australia

    Retatrutide

    20 MG Nov 14, 2026
    United Kingdom

    Retatrutide

    1000 G Nov 14, 2026
    Australia

    retatrutide

    20 MG Nov 13, 2026
    United Kingdom

    retatrutide

    40 MG Nov 13, 2026
    United States

    retatrutide

    10 MG Nov 13, 2026
    United States

    retatrutide

    10 MG Nov 13, 2026
    United States

    Retatrutide

    50 MG Nov 13, 2026
    United Kingdom

    Retatrutide

    10 MG Nov 13, 2026
    United States

    Retatrutide

    600 MG Nov 13, 2026
    United States

    Retatrutide

    5 PCS Nov 12, 2026
    United States

    retatrutide

    20 MG Nov 12, 2026
    United States

    retatrutide

    10 MG Nov 12, 2026
    United States

    retatrutide

    10 MG Nov 12, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.